CompletedPhase 3ACTRN12610001061022

Intranasal oxytocin for the treatment of alcohol dependence

The effect of intranasal oxytocin on alcohol cravings and withdrawal in patients diagnosed with alcohol dependence

Sponsor

University of Sydney

Enrollment

35 participants

Start Date

Sep 20, 2010

Study Type

Interventional

Conditions

Alcohol Dependence

Summary

This double-blind, randomised, placebo controlled trial will examine the safety and efficacy of intranasal oxytocin for the treatment of alcohol dependence. It is hypothesised that participants randomised to the oxytocin condition, compared to participants randomised to the placebo condition will have a higher rate of treatment completion, experience reduced number, severity, and duration of alcohol withdrawal symptoms and will report fewer days of alcohol use at one month follow-up.

Eligibility

Sex: Both males and femalesMin Age: 18 YearssMax Age: 80 Yearss

Plain Language Summary

Simplified for easier understanding

This study tests whether a nasal spray containing oxytocin can help people with alcohol dependence reduce their drinking. Adults aged 18 to 80 who have been diagnosed with alcohol dependence may be eligible, as long as they do not have certain other health conditions.

This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.

Interested in this trial?

Get notified about updates and connect with the research team.